Search Medical Condition
Please enter condition
Please choose location from dropdown

8000 Aarhus, Denmark Clinical Trials

A listing of 8000 Aarhus, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (299) clinical trials

The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon

Patients with chronic diarrhoea after surgical treatment of right-sided colon cancer will be compared to patients without diarrhoea after right-sided colon cancer treatment. All patients will be asked to answer a short questionnaire regarding bowel function, and they will all have standard blood tests taken to exclude non-cancer related causes ...

Phase N/A

3.98 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in patients with manifest Huntington's disease (HD).

Phase

3.98 miles

Learn More »

Prevention of Dermatitis in Epoxy Exposed Workers

Objectives The overarching objective is to reduce the risk of dermatitis and sensitization when working with epoxy resin systems. Specific aims are: To identify work procedures at increased risk of dermal exposure to epoxy resins To examine if fluorescence visualization of dermal exposure to epoxy resins reduces the risk of: ...

Phase N/A

3.98 miles

Learn More »

The Influence of Food Matrix Delivery System on the Bioavailability of Vitamin D3

BACKGROUND The current project is a part of the vitamin D fortification with enhanced bioavailability study program (acronym: DFORT) which is an interdisciplinary project including research groups from Denmark, Spain, and the Netherlands supported by the Danish Innovation Foundation. The overall aim of DFORT is to develop more efficient strategies ...

Phase N/A

3.98 miles

Learn More »

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)

Phase

3.98 miles

Learn More »

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF)

Phase

3.98 miles

Learn More »

Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis

A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with moderate-to-severe plaque-type psoriasis who are candidates for systemic therapy

Phase

3.98 miles

Learn More »

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1 3 8 and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and to investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe chronic hand eczema.

Phase

3.98 miles

Learn More »

The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.

This is a 12-week treatment, singlecenter, open-label, single-arm, dose-selection, proof of concept study to determine a dosage of HSP 90 inhibitor (CUDC-305) that is tolerable and demonstrates preliminary efficacy for use in future efficacy Phase 2 trials. Male or female subjects aged 18 years or older with moderate to severe ...

Phase

3.98 miles

Learn More »